Recursion Pharmaceuticals informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Analice el historial de beneficios de Recursion Pharmaceuticals utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
RXRX | Recursion Pharmaceuticals | -$0.34 | -$0.36 | — | — | $26.08M | $18.60M | — | — | 11/05/2025 | |
RXRX | Recursion Pharmaceuticals | -$0.40 | -$0.35 | -$0.41 | -17.14% | $14.42M | $14.98M | $19.22M | 28.31% | 08/05/2025 | |
RXRX | Recursion Pharmaceuticals | -$0.39 | -$0.52 | -$0.50 | 3.85% | $13.49M | $18.08M | $14.74M | -18.45% | 05/05/2025 | |
RXRX | Recursion Pharmaceuticals | -$0.42 | -$0.42 | -$0.53 | -26.19% | $10.89M | $19.04M | $4.55M | -76.12% | 02/28/2025 | |
RXRX | Recursion Pharmaceuticals | -$0.43 | -$0.35 | -$0.34 | 2.86% | $10.53M | $29.84M | $26.08M | -12.59% | 11/06/2024 | |
RXRX | Recursion Pharmaceuticals | -$0.38 | -$0.40 | -$0.40 | 0.00% | $11.02M | $13.75M | $14.42M | 4.85% | 08/08/2024 | |
RXRX | Recursion Pharmaceuticals | -$0.34 | -$0.42 | -$0.39 | 7.14% | $12.13M | $12.65M | $13.49M | 6.65% | 05/09/2024 | |
RXRX | Recursion Pharmaceuticals | -$0.31 | -$0.45 | -$0.42 | 6.67% | $13.68M | $20.53M | $10.89M | -46.95% | 02/27/2024 | |
RXRX | Recursion Pharmaceuticals | -$0.35 | -$0.38 | -$0.43 | -13.16% | $13.16M | $12.87M | $10.53M | -18.16% | 11/09/2023 | |
RXRX | Recursion Pharmaceuticals | -$0.38 | -$0.37 | -$0.38 | -2.70% | $7.67M | $11.91M | $11.02M | -7.50% | 08/08/2023 | |
RXRX | Recursion Pharmaceuticals | -$0.33 | -$0.35 | -$0.34 | 2.86% | $5.33M | $14.44M | $12.13M | -15.97% | 05/08/2023 | |
RXRX | Recursion Pharmaceuticals | -$0.38 | -$0.29 | -$0.31 | -6.90% | $2.53M | $24.00M | $13.68M | -43.02% | 02/27/2023 | |
RXRX | Recursion Pharmaceuticals | -$0.28 | -$0.38 | -$0.35 | 7.89% | $2.53M | $6.97M | $13.16M | 88.81% | 11/08/2022 | |
RXRX | Recursion Pharmaceuticals | -$0.31 | -$0.40 | -$0.38 | 5.00% | $2.55M | $5.40M | $7.67M | 42.11% | 08/09/2022 | |
RXRX | Recursion Pharmaceuticals | -$1.33 | $0.10 | -$0.33 | -430.00% | $2.56M | $83.95M | $5.33M | -93.65% | 05/10/2022 | |
RXRX | Recursion Pharmaceuticals | -$1.17 | -$0.31 | -$0.38 | -22.58% | $2.70M | $6.07M | $2.53M | -58.27% | 03/23/2022 | |
RXRX | Recursion Pharmaceuticals | -$1.09 | -$0.28 | -$0.28 | 0.00% | $1.02M | $2.62M | $2.53M | -3.28% | 11/10/2021 | |
RXRX | Recursion Pharmaceuticals | -$0.88 | -$0.23 | -$0.31 | -34.78% | — | $2.72M | $2.55M | -6.29% | 08/13/2021 | |
RXRX | Recursion Pharmaceuticals | -$0.85 | — | -$1.33 | — | $60.00K | — | $2.56M | — | 05/12/2021 |
Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
---|---|---|---|---|
Q2 | 2025-08-05 | $-0.41 | $-0.35 | -17.1 % |
Q1 | 2025-05-05 | $-0.50 | $-0.52 | 3.85 % |
Q4 | 2025-02-28 | $-0.53 | $-0.42 | -26.2 % |
Q3 | 2024-11-06 | $-0.34 | $-0.35 | 2.86 % |
Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
---|---|---|---|---|
Q2 | 2025-08-05 | $19.22M | $14.98M | 28.3 % |
Q1 | 2025-05-05 | $14.75M | $18.08M | -18.4 % |
Q4 | 2025-02-28 | $4.55M | $19.04M | -76.1 % |
Q3 | 2024-11-06 | $26.08M | $29.84M | -12.6 % |
Está previsto que Recursion Pharmaceuticals (RXRX) presente resultados el noviembre 5, 2025. Los últimos resultados se publicaron el agosto 5, 2025 para el Q2.
El BPA real fue de $-0.41, que no alcanzó la estimación de $-0.35.
Los ingresos reales fueron $19.2M, que superó la estimación de $15M.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.